We showed that increased levels of NE in LUAD patients could decrease the secretion of chemokine CXCL9 and disturb the immunosuppressive metabolite ADO in tumour cells, thereby reducing the proportion and function of CD8+ T cells in the tumour microenvironment, resulting in anti-PD-1 mAb resistance. This evidence concerns the gene PDCD1 and neoplasm.